Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4522382 | 0.89 | PDE5A (0.57) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL3492717 | 0.86 | PDE5A (0.58) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL4511349 | 0.85 | KMT2A (0.53) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL4515693 | 0.82 | KMT2A (0.80) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL4513057 | 0.81 | SMN1; SMN2 (0.44) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL38484 | 0.77 | PDE5A (0.57) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL4514505 | 0.77 | KMT2A (0.65) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL21153551 | 0.77 | LMNA (0.43) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL4515609 | 0.76 | PDE5A (0.76) | KMT2ALMNARXFP1KCNH2NPSR1 | |
| SCHEMBL3492915 | 0.75 | PDE5A (0.74) | KMT2ARXFP1PDE5ARNASEH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1908765-B1 | THIENOPYRIMIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2014-10-22 | — | — | EP | disclosed |
| US-8377944-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | GOTANDA KOTARO (JP) | 2013-01-24 | — | — | US | disclosed |
| US-8293754-B2 | Thienopyrimidine derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| US-20090203703-A1 | Thienopyrimidine Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-1908765-A1 | THIENOPYRIMIDINE DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2008-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023546-A1 | THIENOPYRIMIDINE DERIVATIVES | PDE9A, BPHL, THOP1 | KMT2A 2650/4885LMNA 4474/4885RXFP1 739/4885 |
| US-20090203703-A1 | Thienopyrimidine Derivatives | PDE9A, BPHL, THOP1 | KMT2A 2650/4885LMNA 4474/4885RXFP1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.